**1. Introduction**

Both the innate and the adaptive branches of the immune system are involved in the elimination of malignant cells. Generally, for the successful elimination of tumors by immunity, the in situ presence of immunoadjuvants and antigens, as well as a nonimmunosuppressor tumor microenvironment, are essential.

Tumor cells commonly express neoantigens, which are different from any other normal protein in the host, or tumor-associated antigens, which are expressed in an unusual tissue or in aberrantly high amounts [1,2]. As a result, one important feature of cancers is their ability to escape immunity, as the immune system is crucially involved in the defense against the development and progression of malignant cells [3].

In certain situations, the immunogenicity of tumors can be enhanced by increasing the local release and exposure of endogenous immunoadjuvants, such as damage-associated molecular patterns (DAMPs). The release of these molecules with a well-defined, immuneactivating pattern is observed in a regulated cell death (RCD) modality known as immunogenic cell death (ICD). In this review we discuss how ICD can help to trigger or boost immune responses against cancer.
